Clinical Study

Oncology

Oncology 2011;81:387–394 DOI: 10.1159/000335263 Received: September 9, 2011 Accepted after revision: November 21, 2011 Published online: January 20, 2012

Impact of Radiotherapy, Chemotherapy and Surgery in Multimodal Treatment of Locally Advanced Esophageal Cancer

Bernhard Berger^a Katharina Stahlberg^a Annina Lemminger^a Martin Bleif^a Claus Belka^b Michael Bamberg^a

^aDepartment of Radiation Oncology, University of Tuebingen, Tuebingen, and ^bDepartment of Radiation Oncology, University of Munich, Munich, Germany

Key Words

Esophageal cancer · Chemoradiation · Radiochemotherapy · Radiotherapy · Surgery

Abstract

Objectives: It was the aim of this study to assess our institutional experience with definitive chemoradiation (CRT) versus induction chemotherapy followed by CRT with or without surgery (C-CRT/S) in esophageal cancer. Methods: We retrospectively analyzed 129 institutional patients with locally advanced esophageal cancer who had been treated by either CRT in analogy to the RTOG 8501 trial (n = 78) or C-CRT/S (n = 51). **Results:** The median, 2- and 5-year overall survival (OS) of the entire collective was 17.6 months, 42 and 24%, respectively, without a significant difference between the CRT and C-CRT/S groups. In C-CRT/S patients, surgery statistically improved the locoregional control (LRC) rates (2-year LRC 73.6 vs. 21.2%; p = 0.003); however, this was translated only into a trend towards improved OS (p = 0.084). The impact of escalated radiation doses (\geq 60.0 vs. < 60.0 Gy) on LRC was detectable only in T1-3 N0-1 M0 patients of the CRT group (2-year LRC 77.8 vs. 42.3%; p = 0.036). Conclusion: Definitive CRT and a trimodality approach including surgery (C-CRT/S) had a comparable outcome in this unselected pa-

KARGER

Fax +41 61 306 12 34 E-Mail karger@karger.ch www.karger.com © 2012 S. Karger AG, Basel 0030–2414/11/0816–0387\$38.00/0

Accessible online at: www.karger.com/ocl tient collective. Surgery and higher radiation doses improve LRC rates in subgroups of patients, respectively, but without effect on OS. Copyright © 2012 S. Karger AG, Basel

Introduction

Almost 20 years ago, the Radiation Therapy Oncology Group (RTOG) 8501 trial defined concomitant chemoradiation (CRT) as the standard of care for locally advanced esophageal cancer [1–3]. Patients treated with 50.0 Gy concurrently with two parallel and two adjuvant cycles of cisplatin and 5-fluorouracil (5-FU) reached a 26% 5-year overall survival (OS) [2]. Since then, technical and procedural treatment options have considerably evolved [4, 5]. However, the results of the original RTOG trial (arm B) have not been prospectively exceeded, and today, the optimal arrangement of CRT remains debatable.

Particular uncertainty concerns the optimal radiation (RT) dose within the concept of definitive CRT. Although the INT 0123 trial did not provide evidence of survival benefits by a boost dose to 64.8 Gy versus standard 50.4 Gy [6], today, most centers routinely escalate the doses to >50.0 Gy. Accordingly, prospective trials on definitive

Dr. Bernhard Berger Department of Radiation Oncology, University of Tuebingen Hoppe-Seyler-Strasse 3 DE-72076 Tuebingen (Germany) Tel. +49 7071 29 85972, E-Mail bernhard.berger@med.uni-tuebingen.de versus neoadjuvant CRT have shown the safety of ≥ 60.0 Gy during definitive CRT [7, 8]. However, a standardized dose escalation during RTOG 8501 analog CRT has not been validated so far.

If surgery is included into a multimodal approach to esophageal cancer, the variability of treatment options is even higher. Neoadjuvant CRT followed by surgery (trimodality treatment) has been randomized prospectively against definitive CRT in at least two large trials [7, 8]. Although differing in treatment schedule and design, both studies confirmed the lack of a survival benefit by surgery, particularly in patients who respond to induction CRT. The inclusion of surgery led to improved locoregional control (LRC) rates; however, perioperative morbidity hampered its translation into improved OS. Thus, as a matter of principle, a non-surgical approach to esophageal cancer is not inferior to trimodality treatment [4, 9].

The CRT regimen applied in the two above-mentioned trials [7, 8] differed from the standard as set by arm B of the RTOG 8501 study: whereas RT was mainly performed as split-course hypofractionated treatment in the French study (2 \times 15.0 Gy) [7], the German trial scheduled induction chemotherapy with cisplatin, etoposide and 5-FU followed by CRT in standard fractionation (40.0 Gy) concomitant to cisplatin and etoposide [8]. Likewise, several institutional reviews reported on differing CRT regimens with or without surgery [10–12].

In light of the broad spectrum of CRT regimens used for multimodal treatment of esophageal cancer, we retrospectively analyzed our own institutional experience which was rather strictly oriented towards the concept of the RTOG 8501 trial (CRT group) and the German phase III trial on trimodality treatment versus definitive CRT (C-CRT/S group), respectively [8].

Patients and Methods

Treatment Protocol

Between 1999 and 2009, 149 patients with primary or recurrent non-metastatic esophageal cancer underwent treatment at the Department of Radiation Oncology, University of Tübingen. The present analysis was limited to patients who received definitive CRT (CRT group, n = 78) or inductive chemotherapy followed by CRT with or without surgery (C-CRT/S group, n = 51). All patients had a biopsy-proven squamous cell carcinoma or adenocarcinoma of the cervical, thoracic or distal esophagus classified as T1–4 N0–1 M0–1a according to the 6.0 TNM criteria. A total of 129 patients met the research criteria and were systematically reviewed for the following data: patient demographics, tumor stage, histology, treatment details and performance, toxicity, treatment outcome and follow-up.

Definitive CRT was performed according to arm B of the RTOG 8501 trial [1] delivering 50.0 Gy with two concomitant and two adjuvant cycles of cisplatin (75 mg/m² on day 1) and 5-FU (1,000 mg/m² on days 1–4). However, in contrast to the 50.0-Gy end dose of the RTOG trial, the RT doses were individually escalated in most patients with respect to tumor localization and size, patient performance and treatment tolerability (median boost dose 10.0 Gy). For RT, we routinely used a computed tomographybased 3D conformal technique or intensity-modulated radiotherapy. The target volume delineation was based on the International Commission on Radiation Units and Measurements 50 definitions and followed the treatment conditions of contemporary trials on esophageal cancer [6, 8, 13].

Trimodality treatment (C-CRT/S) was analogized to the German multicenter trial on neoadjuvant chemotherapy/CRT plus surgery versus definitive CRT, with 10 of 51 patients being randomized in the original study [8]. Treatment consisted of inductive chemotherapy with three courses of cisplatin, etoposide and 5-FU/leucovorin, followed by CRT (30.0–40.0 Gy with concomitant cisplatin on days 2 and 8, etoposide on days 3–5). After restaging, the patients were allocated individually to either surgery or boost RT (60.0- to 65.0-Gy end dose) reflecting the initial tumor localization and size (surgical accessability), the restaging results, medical fitness and the patient's preference.

Statictical Analysis

The main endpoint of this intent-to-treat analysis was to determine OS, LRC and distant control (DC) rates. The survival outcome was calculated using the Kaplan-Meier method with OS, LRC and DC being assessed from the first day of treatment until locoregional recurrence or progress, appearance of distant metastases, and death from any cause, respectively. To compare survival data, the Mantel-Cox log-rank test was used (p values ≤ 0.05 were considered significant). Patient and treatment characteristics were compared using a two-sided Mann-Whitney U test for continuous variables and Fisher's exact test for categorical variables, respectively. Secondary objectives of this analysis were response and toxicity evaluation as well as identification of pretreatment and treatment-related prognostic factors. The treatment outcome was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) by endoscopy and CT scans immediately after the end of neoadjuvant CRT (C-CRT/S group) or 3 months after definitive CRT (CRT group). Treatment-related toxicities were scored according to the Common Terminology Criteria for Adverse Events (version 3.0). To assess the prognostic impact of patient and treatment characteristics, the Cox proportional hazards model was used. Factors proven to be of significance ($p \le 0.05$) were entered into the multivariate analysis. All data were analyzed using PASW 18.0 (SPSS Inc., Chicago, Ill., USA).

Results

Patient and Treatment Characteristics

Of 129 patients included in this analysis, 78 patients (60%) received CRT whereas 51 patients (40%) underwent C-CRT/S. Patient demographics are listed in table 1. An intercohort comparison revealed no relevant differences

Table 1. Patient characteristics

$\begin{array}{ c c c c c c c c c c c c c c c c c c c$				
Age ≤ 60 years 32 (41) 24 (47) 56 (43)>60 years46 (59)27 (53)73 (57)GenderMale 68 (87)43 (84)111 (86)Female10 (13)8 (16)18 (14)HistologySCC 61 (78) 36 (71)97 (75)AC15 (19)15 (29)30 (23)Missing2 (3)2 (2)GradingG17 (9)5 (10)12 (9)G239 (46)30 (59)69 (53)G322 (28)14 (27)36 (28)Missing10 (13)2 (4)12 (9)Primary tumor subsiteProximal third19 (24)9 (18)28 (22)Mid third32 (41)21 (41)53 (41)Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor statusT14 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal statusN019 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)StageI/II23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)				Entire cohort (n = 129)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Median age, years	63 [43-78]	60 [42-76]	62 [42-78]
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Age			
GenderMale68 (87)43 (84)111 (86)Female10 (13)8 (16)18 (14)HistologySCC61 (78)36 (71)97 (75)AC15 (19)15 (29)30 (23)Missing2 (3)2 (2)Grading $G1$ 7 (9)5 (10)12 (9)G239 (46)30 (59)69 (53)G322 (28)14 (27)36 (28)Missing10 (13)2 (4)12 (9)Primary tumor subsite $Proximal third$ 19 (24)9 (18)28 (22)Mid third32 (41)21 (41)53 (41)Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor status Tx (nodal recurrence)4 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal status $N0$ 19 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)Stage I/II 23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	≤60 years	32 (41)	24 (47)	56 (43)
Male68 (87)43 (84)111 (86)Female10 (13)8 (16)18 (14)Histology SCC 61 (78)36 (71)97 (75)AC15 (19)15 (29)30 (23)Missing2 (3)2 (2)Grading (3) 2 (2)Grading (3) 2 (2)G239 (46)30 (59)69 (53)G322 (28)14 (27)36 (28)Missing10 (13)2 (4)12 (9)Primary tumor subsite $Proximal third$ 19 (24)9 (18)Proximal third19 (24)9 (18)28 (22)Mid third32 (41)21 (41)53 (41)Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor status Tx (nodal recurrence)4 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal status $N0$ 19 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)Stage I/III 23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	>60 years	46 (59)	27 (53)	73 (57)
Female10 (13)8 (16)18 (14)HistologySCC61 (78)36 (71)97 (75)AC15 (19)15 (29)30 (23)Missing2 (3)2 (2)Grading (3) 2 (2)Gading (3) 2 (2)G239 (46)30 (59)69 (53)G322 (28)14 (27)36 (28)Missing10 (13)2 (4)12 (9)Primary tumor subsite $Proximal third$ 19 (24)9 (18)Proximal third19 (24)9 (18)28 (22)Mid third32 (41)21 (41)53 (41)Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor status Tx (nodal recurrence)4 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal status $N0$ 19 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)Stage I/III 23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	Gender			
HistologySCC $61(78)$ $36(71)$ $97(75)$ AC $15(19)$ $15(29)$ $30(23)$ Missing $2(3)$ $2(2)$ Grading $(1 79)$ $5(10)$ $12(9)$ G2 $39(46)$ $30(59)$ $69(53)$ G3 $22(28)$ $14(27)$ $36(28)$ Missing $10(13)$ $2(4)$ $12(9)$ Primary tumor subsite $Proximal third$ $19(24)$ $9(18)$ $28(22)$ Mid third $32(41)$ $21(41)$ $53(41)$ Distal third $21(27)$ $14(27)$ $35(27)$ GEJ $6(8)$ $7(14)$ $13(10)$ Tumor status Tx (nodal recurrence) $4(5)$ $4(3)$ T2 $7(9)$ $2(4)$ $9(7)$ T3 $48(62)$ $47(92)$ $95(74)$ T4 (p = 0.008) $15(19)$ $2(4)$ $17(13)$ Nodal status $N0$ $19(24)$ $8(16)$ $27(21)$ N1 $59(76)$ $43(84)$ $102(79)$ Stage I/II $23(29)$ $10(20)$ $33(26)$ III $49(63)$ $40(78)$ $89(69)$	Male	68 (87)	43 (84)	111 (86)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Female	10 (13)	8 (16)	18 (14)
AC15 (19)15 (29)30 (23)Missing2 (3)2 (2)Grading $(31 - 7 (9) - 5 (10) - 12 (9)$ G17 (9)5 (10) - 12 (9)G239 (46)30 (59)69 (53)G322 (28)14 (27)36 (28)Missing10 (13)2 (4)12 (9)Primary tumor subsite $(41) - 21 (41) - 23 (41)$ 28 (22)Mid third32 (41)21 (41)53 (41)Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor status Tx (nodal recurrence)4 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal status $N0$ 19 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)Stage I/II 23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	Histology			
Missing2 (3)2 (2)Grading $G1$ 7 (9)5 (10)12 (9)G239 (46)30 (59)69 (53)G322 (28)14 (27)36 (28)Missing10 (13)2 (4)12 (9)Primary tumor subsite $Proximal third$ 19 (24)9 (18)28 (22)Mid third32 (41)21 (41)53 (41)Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor status Tx (nodal recurrence)4 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal status $N0$ 19 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)Stage I/III 23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	SCC	61 (78)	36 (71)	97 (75)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	AC	15 (19)	15 (29)	30 (23)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Missing	2 (3)		2 (2)
G239 (46)30 (59)69 (53)G322 (28)14 (27)36 (28)Missing10 (13)2 (4)12 (9)Primary tumor subsite9 (18)28 (22)Mid third32 (41)21 (41)53 (41)Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor status4 (5)4 (3)T14 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal statusN019 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)StageI/II23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	Grading			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	G1	7 (9)	5 (10)	12 (9)
Missing10 (13)2 (4)12 (9)Primary tumor subsite 2 2 10 (13) 2 2 Proximal third19 (24)9 (18)28 (22)Mid third32 (41)21 (41)53 (41)Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor status $T1$ 4 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal status $N0$ 19 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)Stage I/II 23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	G2	39 (46)	30 (59)	69 (53)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	G3	22 (28)	14 (27)	36 (28)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Missing	10 (13)	2 (4)	12 (9)
Mid third $32 (41)$ $21 (41)$ $53 (41)$ Distal third $21 (27)$ $14 (27)$ $35 (27)$ GEJ $6 (8)$ $7 (14)$ $13 (10)$ Tumor statusTx (nodal recurrence) $4 (5)$ $4 (3)$ T2 $7 (9)$ $2 (4)$ $9 (7)$ T3 $48 (62)$ $47 (92)$ $95 (74)$ T4 (p = 0.008) $15 (19)$ $2 (4)$ $17 (13)$ Nodal statusN0 $19 (24)$ $8 (16)$ $27 (21)$ N1 $59 (76)$ $43 (84)$ $102 (79)$ StageI/II $23 (29)$ $10 (20)$ $33 (26)$ III $49 (63)$ $40 (78)$ $89 (69)$	Primary tumor subsite			
Distal third21 (27)14 (27)35 (27)GEJ6 (8)7 (14)13 (10)Tumor statusTx (nodal recurrence)4 (5)4 (3)T14 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal statusN019 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)StageI/II23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	Proximal third	19 (24)	9 (18)	28 (22)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Mid third	32 (41)	21 (41)	53 (41)
Tumor statusTx (nodal recurrence)4 (5)4 (3)T14 (5)4 (3)T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal statusN019 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)StageI/II23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	Distal third	21 (27)	14 (27)	35 (27)
$\begin{array}{ccccccc} {\rm Tx} \mbox{ (nodal recurrence)} & 4 \mbox{ (5)} & 4 \mbox{ (3)} \\ {\rm T1} & 4 \mbox{ (5)} & 4 \mbox{ (3)} \\ {\rm T2} & 7 \mbox{ (9)} & 2 \mbox{ (4)} & 9 \mbox{ (7)} \\ {\rm T3} & 48 \mbox{ (62)} & 47 \mbox{ (92)} & 95 \mbox{ (74)} \\ {\rm T4} \mbox{ (p = 0.008)} & 15 \mbox{ (19)} & 2 \mbox{ (4)} & 17 \mbox{ (13)} \\ {\rm Nodal status} & & & \\ {\rm N0} & 19 \mbox{ (24)} & 8 \mbox{ (16)} & 27 \mbox{ (21)} \\ {\rm N1} & 59 \mbox{ (76)} & 43 \mbox{ (84)} & 102 \mbox{ (79)} \\ {\rm Stage} & & & \\ {\rm I/II} & 23 \mbox{ (29)} & 10 \mbox{ (20)} & 33 \mbox{ (26)} \\ {\rm III} & 49 \mbox{ (63)} & 40 \mbox{ (78)} & 89 \mbox{ (69)} \\ \end{array}$	GEJ	6 (8)	7 (14)	13 (10)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Tumor status			
T27 (9)2 (4)9 (7)T348 (62)47 (92)95 (74)T4 (p = 0.008)15 (19)2 (4)17 (13)Nodal status $N0$ 19 (24)8 (16)27 (21)N159 (76)43 (84)102 (79)Stage I/II 23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	Tx (nodal recurrence)	4 (5)		4 (3)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Τ1	4 (5)		4 (3)
$\begin{array}{cccccccc} T4 \ (p=0.008) & 15 \ (19) & 2 \ (4) & 17 \ (13) \\ Nodal status & & & \\ N0 & 19 \ (24) & 8 \ (16) & 27 \ (21) \\ N1 & 59 \ (76) & 43 \ (84) & 102 \ (79) \\ Stage & & \\ I/II & 23 \ (29) & 10 \ (20) & 33 \ (26) \\ III & 49 \ (63) & 40 \ (78) & 89 \ (69) \\ \end{array}$	Τ2	7 (9)	2 (4)	9 (7)
Nodal status 19 (24) 8 (16) 27 (21) N1 59 (76) 43 (84) 102 (79) Stage 1/II 23 (29) 10 (20) 33 (26) III 49 (63) 40 (78) 89 (69)	Т3	48 (62)	47 (92)	95 (74)
N0 19 (24) 8 (16) 27 (21) N1 59 (76) 43 (84) 102 (79) Stage I/II 23 (29) 10 (20) 33 (26) III 49 (63) 40 (78) 89 (69)	T4 (p = 0.008)	15 (19)	2 (4)	17 (13)
N1 59 (76) 43 (84) 102 (79) Stage I/II 23 (29) 10 (20) 33 (26) III 49 (63) 40 (78) 89 (69)	Nodal status			
Stage I/II 23 (29) 10 (20) 33 (26) III 49 (63) 40 (78) 89 (69)	N0	19 (24)	8 (16)	27 (21)
I/II23 (29)10 (20)33 (26)III49 (63)40 (78)89 (69)	N1	59 (76)	43 (84)	102 (79)
III 49 (63) 40 (78) 89 (69)	Stage			
	I/II	23 (29)	10 (20)	33 (26)
IVA 6 (8) 1 (2) 7 (5)	III	49 (63)	40 (78)	89 (69)
	IVA	6 (8)	1 (2)	7 (5)

Figures in parentheses are percentages; figures in brackets are ranges. SCC = Squamous cell carcinoma; AC = adenocarcinoma; GEJ = gastroesophageal junction.

except for a higher frequency of T4 tumors in the CRT group (19 vs. 4%; p = 0.008). Corresponding to the higher frequency of obstructive tumors in the CRT group, more patients were dependent on feeding tubes before treatment (27 vs. 10%; p = 0.024). The treatment differences between the two groups are shown in table 2. According to the differing treatment intention, patients in the CRT group received significantly higher RT doses (median RT dose 60.0 vs. 40.0 Gy; p < 0.001) and had greater planning target volumes (median 842 vs. 706 ml; p < 0.001).

Treatment Performance and Tolerability

All patients scheduled for CRT received the RT dose as planned. In contrast, chemotherapy had to be modified or even aborted in about one third of patients (n = 28) due to non-specific deterioration of performance status (n = 10), hematological toxicity (n = 7) or denial of further treatment (n = 8). In the C-CRT/S group, the RT dose was limited to 36.0 Gy without chemotherapy due to progressive disease in 1 patient scheduled for 40.0 Gy. With respect to chemotherapy, at least two inductive cycles were accomplished by all patients. Grade 3/4 hematological side effects required dose reductions during the following courses in 9 patients. Five patients proceeded with RT alone instead of concomitant CRT due to progressive disease (n = 2), acute renal failure (n = 1) and hematological toxicity (n = 2). Fifty-seven patients (73%) in the CRT group and 49 patients (96%) in the C-CRT/S group received more than two thirds of the chemotherapy as planned (table 2). Among the 51 patients of the C-CRT/S group, 28 patients were scheduled for surgery. However, at the time of surgery, 9 patients were found to be irresectable or showed loss of distant tumor control; the remainder (n = 19) received a complete tumor resection (R0).

With 7 patients being lost by early death or incomplete follow-up, 122 patients were assessable for late treatmentrelated toxicity (table 3). Of 86 patients who had not received a feeding tube before or during treatment, 12 patients (14%) developed a late tube-dependent dysphagia. Repeated balloon dilatation or stenting was necessary in 33 patients (27%). Tracheoesophageal fistulae occurred in 19 patients (16%). Five fatal events (4%) were undoubtedly related to treatment: 3 patients died of postoperative complications following surgery (anastomotic leakage) and 2 patients developed a fatal tracheoesophageal fistula (CRT group). The incidence of fatal events did not statistically differ between the two treatment groups (p =0.66).

Survival and Tumor Control

The median follow-up time for patients alive was 3 years (36.1 months, range 5.6–124.3). On intent-to-treat analysis of all patients, the median, 2- and 5-year OS probability was 17.6 months (95% confidence interval 13.0–22.0), 42 and 24%, respectively. The 2- and 5-year LRC rates were 56 and 50%, respectively, and the actuarial DC rates reached 67 and 52%, respectively.

Comparing the CRT and C-CRT/S groups, there was no significant difference in terms of OS (2-year OS 39.1 vs. 45.1%; p = 0.89) (fig. 1a) and DC rates (2-year DC 71.2 vs. 62.4%; p = 0.091). However, patients in the CRT group

Oncology 2011;81:387-394

Table 2. Treatment details

	CRT (n = 78)	C-CRT/S (n = 51)	Entire cohort (n = 129)	р
	(/	(/	()	
Surgery	()			
None	75 (96)	32 (63)	107 (83)	
Preceding CRT	3 (4)		3 (2)	
Following C-CRT		19 (37)	19 (15)	< 0.001
Median RT dose, Gy	60 [50-72]	40 [30-70]	60 [30-72]	< 0.001
RT dose				
<50 Gy		28 (55)	28 (22)	< 0.001
≥50 Gy	78 (100)	23 (45)	101 (78)	
<60 Gy	32 (41)	30 (59)	62 (48)	0.07
≥60 Gy	46 (59)	21 (41)	67 (52)	
RT technique				
IMRT	22 (28)	1 (2)	23 (18)	< 0.001
3D conformal	56 (72)	50 (98)	106 (82)	
Median PTV, ml	842 [240-2,212]	706 [334–1,529]	788 [240-2,212]	
Inductive CT				
Yes	8 (10)	51 (100)	59 (46)	< 0.001
No	70 (90)		70 (54)	
Adherence to CT				
100%	47 (60)	39 (76)	86 (67)	0.06
<100%	31 (40)	12 (24)	43 (33)	
\geq two thirds	57 (73)	49 (96)	106 (82)	0.01
< two thirds	21 (27)	2 (4)	23 (18)	

Figures in parentheses are percentages; figures in brackets are ranges. IMRT = Intensity-modulated radiotherapy; PTV = planning target volume.

Table 3. Acute and late toxicity

Acute toxicity	CRT (n = 78)	C-CRT (n = 51)	C-CRT/S (n = 51)	р
Hematological grade 3/4	6 (7)	7 (14)	10 (20)	< 0.001
Non-hematological				
Cardiovascular (arrhythmia/general) grade 5	2 (3)			
Tracheoesophageal fistula/bleeding grade 5	1 (1)			
Anastomotic leakage/aspiration pneumonia grade 5		3 (6)		
Acute dysphagia				
Pre-existing gastrostomy dependency ¹	21 (27)	5 (10)		0.024
Esophagitis requiring gastrostomy during treatment ²	11/57 (19)	4/46 (9)	2/46 (4)	0.19
Late toxicity	CRT (n = 73)	C-CRT (n = 49)	C-CRT/S (n = 49)	р
Late tracheoesophageal fistula	8 (10)	9 (18)	2 (4)	0.077
Late tracheoesophageal fistula/bleeding grade 5	2 (3)			
Chronic dysphagia				
Esophageal stricture requiring dilatation/stenting	18 (25)	12 (24)	3 (6)	0.41
Esophageal stricture requiring late gastrostomy ²	9/46 (20)	2/40 (5)	1/40 (3)	0.13

Figures in parentheses are percentages. ¹ Indicating patients who needed to supplement most of their diet with gastrostomy tube feedings before treatment. ² Percentages refer to patients at risk.




Fig. 1. Kaplan-Meier curves indicating OS (**a**) and LRC (**b**) stratified for the CRT and the C-CRT/S group (p values determined by log-rank test).




Fig. 2. Kaplan-Meier curves indicating OS (**a**) and LRC (**b**) in the C-CRT/S group stratified by surgery (p values determined by log-rank test).

showed significantly better LRC rates (2-year LRC 70.2 vs. 40.4%; p = 0.003) (fig. 1b). In the C-CRT/S group, the inclusion of surgery led to significantly improved LRC rates (2-year LRC with and without surgery 73.6 vs. 21.2%, respectively; p = 0.003); however, this was translated only into a trend towards improved OS (2-year OS 63.2 vs. 34.4%; p = 0.084) (fig. 2). Comparing the surgically re-

sected patients of the C-CRT/S group with all other patients, a benefit was detectable for both OS and LRC, respectively, but this did not reach statistical significance (2-year OS 63.2 vs. 37.5%, p = 0.18; 2-year LRC 73.6 vs. 52.0%, p = 0.27).

In the CRT group, patients with T4 tumors or M1a stage showed pronouncedly poor LRC and OS rates (2-

Multidisciplinary Treatment of Locally Advanced Esophageal Cancer Oncology 2011;81:387-394




Fig. 3. Kaplan-Meier curves indicating OS (**a**) and LRC (**b**) in the T1–3 N0–1 M0 subgroup of the CRT group stratified by RT doses <60.0 and \geq 60.0 Gy (p values determined by log-rank test).

year OS T1–3 vs. T4 43.6 vs. 13.3%; p = 0.003). Accordingly, when excluding those patients, 43.9 and 27.4% 2and 5-year OS rates were reached in the T1–3 N0–1 M0 subgroup, respectively. With regard to RT doses, all patients who received ≥ 60 Gy had better OS and LRC rates than those with <60 Gy, without reaching statistical significance (p = 0.32 vs. 0.31, respectively). A significant improvement in LRC rates by higher RT doses was only detectable in the T1–3 N0–1 M0 subgroup (2-year LRC 77.8 vs. 42.3%; p = 0.036). However, again, this was not translated into improved OS (2-year OS 49.0 vs. 32.7%; p = 0.41) (fig. 3).

Treatment Outcome and Prognostic Factors

One hundred and twenty-four of 129 patients (92%) were assessable for treatment response. The overall response rate (complete response plus partial response) was 77%, with almost equal portions of patients achieving complete and partial response, respectively. At the time of the present analysis, 93 patients of the entire collective had died (64% of the CRT group and 84% of the C-CRT/S group). Information on tumor control shortly before death was available in 90 patients. The majority (81%) had died of locoregional or distant tumor progression with a significantly higher incidence of both locoregional and distant relapses in the C-CRT/S group compared to the CRT group (locoregional relapse 59 vs. 23%, p < 0.001; distant progression 45 vs. 23%, p = 0.017).

To derive conclusions specific to either CRT or C-CRT/S, the impact of tumor- and treatment-related factors was evaluated separately for both treatment groups. In CRT patients, the univariate analysis showed the following covariates to be significantly prognostic of OS: tumor grading, T category (T1–3 vs. T4), nodal status, adherence to chemotherapy, and tumor response. Statistical significance was maintained multivariately except for the nodal status (table 4). In the C-CRT/S group, the tumor response was the only statistically significant factor, with surgery reaching just borderline significance (p = 0.09). Regarding the influence of different RT doses (<60 vs. \geq 60 and <50 vs. \geq 50 Gy in the CRT and C-CRT/S group, respectively), unequivocal effects were not detectable.

Discussion

With a 2- and 5-year OS of 42 and 24%, respectively, the survival outcome of this unselected population is in line with results yielded by large randomized trials on definitive CRT or trimodality treatment [1, 2, 7, 8]. In view of the high proportion of advanced disease (87% T3/4 tumors) and positive lymph nodes (79%), this result is remarkable. In fact, the baseline characteristics of our patients were poorer than reported by other institutional series [10–12, 14]. With respect to our CRT group, the OS and LRC rates are better than those achieved in the ran-

Table 4. Prognostic factors on OS (CRT group)

	Univariate analysis	Univariate analysis		Multivariate analysis	
	unadjusted HR	р	adjusted HR	р	
Age					
≤60 versus >60 years	1.08 (0.62–1.9)	0.78			
Gender					
Male versus female	0.95 (0.43-2.11)	0.9			
Histology					
AC versus SCC	0.44 (0.19–1.03)	0.059			
Grading					
G1/2 versus G3	2.74 (1.3-5.74)	0.008	2.98 (1.24-7.17)	0.015	
Tumor stage					
T1-2 versus T3	0.32 (0.1-1.06)	0.062			
T1-3 versus T4	0.4 (0.22-0.78)	0.005	0.33 (0.14-0.8)	0.014	
Nodal status					
N0 versus N1	0.43 (0.19-0.95)	0.036	0.38 (0.12-1.23)	0.11	
RT dose					
≥60 versus <60 Gy	0.76 (0.43-1.32)	0.324			
Adherence to CT					
<100 versus 100%	2.78 (1.58-4.83)	< 0.001	3.48 (1.11-10.93)	0.033	
< two thirds versus \geq two thirds	1.89 (1.04-3.43)	0.037	0.42 (0.13-1.34)	0.143	
Response					
Less than PR versus PR/CR	3.0 (1.56-5.8)	0.001	1.13 (0.41-3.11)	0.82	
Less than CR versus CR	7.09 (3.25-15.5)	< 0.001	5.0 (1.83-13.69)	0.002	

Figures in parentheses are 95% confidence intervals. AC = Adenocarcinoma; SCC = squamous cell carcinoma; PR = partial remission; CR = complete remission; HR = hazard ratio (>1 indicative of worse survival).

domized and non-randomized part of the RTOG 8501 study [2]. This difference is further extended if one confines the analysis to the RTOG 8501 analog T1–3 N0–1 M0 patient subgroup which reached a durable 2-year LRC rate of 68% corresponding to a 2- and 5-year OS of 44 and 27%, respectively. Thus, the present review reports a successful translation of phase III evidence into daily clinical practice.

The high rate of adherence to protocol may have influenced the positive outcome of definitive CRT. In fact, full completion of therapy is an important endpoint for patients with esophageal cancer who often interrupt treatment due to toxicity and a worsening performance status. Accordingly, in the RTOG 8501 trial, 7% of patients did not receive full RT doses, and only 54% of patients completed all four cycles of chemotherapy [1]. In contrast, we here report complete adherence to RT, with 73% of patients having tolerated more than two thirds of chemotherapy.

Regarding the impact of escalated RT doses, we found an unequivocal effect only on LRC in the T1–3 N0–1 M0 subgroup (CRT collective). Apart from statistical reasons due to the small sample size, this result most probably stems from the poor outcome of patients with T4 tumors irrespective of RT doses and treatment schedule. In fact, a dose-response relationship >50 Gy has not been confirmed prospectively in esophageal cancer [6], and even retrospective studies are sparse. Institutional series reporting on a dose-response relationship predominantly concern the dose range of 30.0–50.0 Gy [15]. Information on doses >50.0 Gy is mostly derived from series on radiotherapy alone or on heterogeneously designed CRT [14-18]. Recently, RT doses >54.0 Gy have been multivariately identified to impact OS in an unselected study population subjected to definitive CRT mainly based on mitomycin C [14]. However, in the absence of more detailed data on LRC and DC as well as on treatment-related toxicity, the issue of RT dose escalation >50 Gy needs further investigation. To conclude, although affected by all the methodological drawbacks of a retrospective institutional study, our analysis firstly confirms improved LRC rates by escalated RT doses >50.0 Gy in the context of definitive CRT strictly analogized to the RTOG 8501 trial.

Oncology 2011;81:387-394

As to trimodality treatment, randomized data have shown the positive impact of surgery on LRC in esophageal cancer without translation into improved OS [7, 8]. In the present analysis, these results have been confirmed by the comparison of patients treated surgically in the C-CRT/S group and those treated in analogy to the RTOG 8501 concept. Within our C-CRT/S cohort, surgery significantly improved the LRC rates; however, this could not compensate for the pronouncedly poor results of C-CRT/S patients who were not operated and stopped treatment after insufficient RT doses (median 40.0 Gy). In contrast, inferior LRC and DC rates within the C-CRT/S group did not lead to inferior OS rates when compared to patients subjected to CRT; one possible explanation would be the higher amount of non-tumor-related deaths in the CRT group. However, beyond doubt, a selection bias resulting from the non-randomized allocation of patients to the two individually adapted treatment concepts limits final statements.

CRT performed in accordance to RTOG 8501 (RT dose range 59.4–66.6 Gy) has been compared to CRT plus surgery (RT dose range 41.4–50.4 Gy) in one other single analysis [12]. Further available reports are characterized by differing radiotherapy schedules [10, 16] or variable chemotherapy regimens with lower cumulative cisplatin doses or even without cisplatin [11, 14, 16]. In conclusion, the successful translation of LRC benefits into improved OS is a challenge regardless of whether LRC is achieved by surgery or high-dose CRT. In this regard, the optimal management of treatment-related toxicities and individual comorbid factors is of high importance.

Disclosure Statement

There are no conflicts of interest.

References

- Herskovic A, Martz K, al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593–1598.
- 2 Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623–1627.
- 3 al-Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277–284.
- 4 Berger B, Belka C: Evidence-based radiation oncology: esophagus. Radiother Oncol 2009; 92:276–290.
- 5 Malthaner RA, Wong RK, Rumble RB, Zuraw L: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004;2:35.
- 6 Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–1174.

- 7 Bedenne L, Michel P, Bouche O, et al: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160–1168.
- 8 Stahl M, Stuschke M, Lehmann N, et al: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310–2317.
- 9 Adams R, Morgan M, Mukherjee S, et al: A prospective comparison of multidisciplinary treatment of esophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol 2007;33:307–313.
- 10 Delcambre C, Jacob JH, Pottier D, et al: Localized squamous-cell cancer of the esophagus: retrospective analysis of three treatment schedules. Radiother Oncol 2001;59:195– 201.
- 11 Denham JW, Burmeister BH, Lamb DS, et al: Factors influencing outcome following radio-chemotherapy for esophageal cancer. The Trans Tasman Radiation Oncology Group (TROG). Radiother Oncol 1996;40: 31-43.
- 12 Rades D, Schulte R, Yekebas EF, et al: Radio(chemo)therapy plus resection versus radio(chemo)therapy alone for the treatment of stage III esophageal cancer. Strahlenther Onkol 2007;183:10–16.

- 13 Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086–1092.
- 14 Wolf M, Zehentmayr F, Niyazi M, et al: Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol 2010; 186:374–381.
- 15 Zhang Z, Liao Z, Jin J, et al: Dose-response relationship in locoregional control for patients with stage II–III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:656–664.
- 16 Seung SK, Smith JW 2nd, Ross HJ: Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer. Dis Esophagus 2008;21:589–595.
- 17 Shi XH, Yao W, Liu T: Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 1999;51:21–26.
- 18 Mizumoto M, Sugahara S, Nakayama H, et al: Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther Onkol 2010;186:482–488.